Real-World study tracks ribociclib combo in elderly breast cancer
NCT ID NCT06625333
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 329 older patients (65 years and up) with HR+HER2- advanced breast cancer who are taking ribociclib combined with endocrine therapy as their first or second treatment. Researchers are tracking quality of life, treatment effectiveness, and safety in real-world clinics across Russia. The goal is to see how well this therapy works in everyday practice for this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ribociclib combined with endocrine therapy (aromatase inhibitor or fulvestrant)
What this could lead to
If successful, this could help doctors understand how well this treatment works and affects quality of life in older patients, leading to better care for this age group.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the treatment. It only includes patients in Russia, so findings may not apply elsewhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Arkhangelsk, 163045, Russia
-
Novartis Investigative Site
Barnaul, 656045, Russia
-
Novartis Investigative Site
Bryansk, 241028, Russia
-
Novartis Investigative Site
Chelyabinsk, 454080, Russia
-
Novartis Investigative Site
Irkutsk, 664035, Russia
-
Novartis Investigative Site
Kemerovo, 650036, Russia
-
Novartis Investigative Site
Khabarovsk, 680042, Russia
-
Novartis Investigative Site
Khanty-Mansiysk, 628012, Russia
-
Novartis Investigative Site
Kirov, 610021, Russia
-
Novartis Investigative Site
Krasnoyarsk, 660022, Russia
-
Novartis Investigative Site
Obninsk, 249036, Russia
-
Novartis Investigative Site
Perm, 614066, Russia
-
Novartis Investigative Site
Rostov-on-Don, 344006, Russia
-
Novartis Investigative Site
Saint Petersburg, 194291, Russia
-
Novartis Investigative Site
Saint Petersburg, 197758, Russia
-
Novartis Investigative Site
Tambov, 392000, Russia
-
Novartis Investigative Site
Tver', 170008, Russia
-
Novartis Investigative Site
Ufa, 450054, Russia
-
Novartis Investigative Site
Yaroslavl, 150054, Russia
-
Novartis Investigative Site
Yekaterinburg, 620036, Russia